Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011, 121: 2750-2767.
Article
PubMed
CAS
PubMed Central
Google Scholar
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, et al: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2013, 486: 395-399.
Google Scholar
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, Carter C, Chu A, Chuah E, Chun H-JE, Coope RJN, Dhalla N, Guin R, Hirst C, Hirst M, Holt RA, Lee D, Li HI, Mayo M, Moore RA, Mungall AJ, et al: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490: 61-70.
Article
CAS
Google Scholar
Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer. 2009, 9: 28-39.
Article
PubMed
Google Scholar
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science. 2002, 298: 1912-1934.
Article
PubMed
CAS
Google Scholar
Sawyers C: Targeted cancer therapy. Nature. 2004, 432: 294-297.
Article
PubMed
CAS
Google Scholar
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348: 994-1004.
Article
PubMed
Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139.
Article
PubMed
CAS
Google Scholar
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304: 1497-1500.
Article
PubMed
CAS
Google Scholar
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004, 101: 13306-13311.
Article
PubMed
CAS
PubMed Central
Google Scholar
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010, 363: 809-819.
Article
PubMed
CAS
PubMed Central
Google Scholar
Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou S-HI, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim W-H, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363: 1693-1703.
Article
PubMed
CAS
PubMed Central
Google Scholar
Demetri GD, Mehren von M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Bin Peng, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347: 472-480.
Article
PubMed
CAS
Google Scholar
Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014, 371: 1963-1971.
Article
PubMed
PubMed Central
Google Scholar
Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature Biotechnology. 2011, 29: 1039-1045.
Article
PubMed
CAS
PubMed Central
Google Scholar
Davis MI, Hunt JP, Herrgard S, Pietro Ciceri, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP: Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology. 2011, 29: 1046-1051.
Article
PubMed
CAS
Google Scholar
Yoo M, Shin J, Kim J, Ryall KA, Lee K, Lee S, Kang J, Tan AC: DSigDB: drug signatures database for gene set analysis. Bioinformatics. 2015, 31: 3069-3071.
Article
PubMed
Google Scholar
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012, 483: 603-607.
Article
PubMed
CAS
PubMed Central
Google Scholar
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012, 483: 570-575.
Article
PubMed
CAS
PubMed Central
Google Scholar
Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJ: Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 2012, 41: D955-D961.
Article
PubMed
PubMed Central
Google Scholar
Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS-Y, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL: An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013, 154: 1151-1161.
Article
PubMed
CAS
PubMed Central
Google Scholar
Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer. 2006, 6: 813-823.
Article
PubMed
CAS
Google Scholar
Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR: Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Molecular Cancer Therapeutics. 2015, 14: 298-306.
Article
PubMed
CAS
PubMed Central
Google Scholar
Gujral TS, Peshkin L, Kirschner MW: Exploiting polypharmacology for drug target deconvolution. Proc Natl Acad Sci USA. 2014, 111: 5048-5053.
Article
PubMed
CAS
PubMed Central
Google Scholar
Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC: Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics. 2015, 31: 3799-3806. doi:10.1093/bioinformatics/btv427
PubMed
Google Scholar
Kim J, Yoo M, Kang J, Tan AC: K-Map: connecting kinases with therapeutics for drug repurposing and development. Human Genomics. 2013, 7: 20-
Article
PubMed
PubMed Central
Google Scholar
Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC: Bioinformatics-driven discovery of rational combination for over- coming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 2014, 30: 2393-2398.
Article
PubMed
CAS
PubMed Central
Google Scholar
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR: The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science. 2006, 313: 1929-1935.
Article
PubMed
CAS
Google Scholar
Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ: Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clinical Cancer Research. 2013, 19: 291-303.
Article
PubMed
CAS
PubMed Central
Google Scholar
Tentler JJ, Ionkina A, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR: p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 2015, 14: 1117-1129.
Article
PubMed
CAS
Google Scholar
Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM: A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci USA. 2006, 103: 3775-3780.
Article
PubMed
CAS
PubMed Central
Google Scholar
Liang JJ, Wang H, Rashid A, Tan T-H, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H: Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clinical Cancer Research. 2008, 14: 7043-7049.
Article
PubMed
CAS
Google Scholar
Borges S, Storz P: Protein kinase D isoforms: new targets for therapy in invasive breast cancers?. Expert Review of Anticancer Therapy. 2013, 13: 895-898.
Article
PubMed
CAS
Google Scholar
Huck B, Duss S, Hausser A, Olayioye MA: Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem. 2014, 289: 3138-3147.
Article
PubMed
CAS
PubMed Central
Google Scholar
Corkery B, Crown J, Clynes M, O'Donovan N: Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009, 20: 862-867.
Article
PubMed
CAS
Google Scholar
Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT: Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Molecular Cancer Therapeutics. 2007, 6: 2168-2177.
Article
PubMed
CAS
PubMed Central
Google Scholar
Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB: Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks. Cell. 2012, 149: 780-794.
Article
PubMed
CAS
PubMed Central
Google Scholar
Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007, 105: 319-326.
Article
PubMed
CAS
Google Scholar
Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009, 137: 821-834.
Article
PubMed
CAS
Google Scholar
Huang H-L, Chiang C-H, Hung W-C, Hou M-F: Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer. Oncotarget. 2015, 6: 995-1007.
Article
PubMed
PubMed Central
Google Scholar
Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J: TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012, 148: 639-650.
Article
PubMed
CAS
PubMed Central
Google Scholar
Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P: Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clinical Cancer Research. 2009, 15: 6327-6340.
Article
PubMed
CAS
PubMed Central
Google Scholar
Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA: FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Research. 2013, 73: 1981-1992.
Article
PubMed
CAS
PubMed Central
Google Scholar
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A: MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012, 209: 679-696.
Article
PubMed
CAS
PubMed Central
Google Scholar
Kang J, Sergio CM, Sutherland RL, Musgrove EA: Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014, 14: 32-
Article
PubMed
PubMed Central
Google Scholar
Berlow N, Davis LE, Cantor EL, Séguin B, Keller C, Pal R: A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC Bioinformatics. 2013, 14: 239-
Article
PubMed
CAS
PubMed Central
Google Scholar
Tran TP, Ong E, Hodges AP, Paternostro G, Piermarocchi C: Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression. 2014, 8: 74-
Google Scholar
Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Boer Den ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM: Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 2013, 73: 285-296.
Article
PubMed
CAS
PubMed Central
Google Scholar